You are here:

Dr Guy Simpson

Research Fellow Oncology

Qualifications: BSc PhD

Email:
Phone: Work: 01483 68 8600
Room no: 30 PGM 02

Office hours

9am to 5pm Mon-Fri

Further information

Biography

2004 PhD        Optimising therapeutic herpes simplex vectors for cancer.

                        BioVex Ltd/UCL The Windeyer Institute, 46 Cleveland Street, London.

 

1997 MPhil     Human endogenous retroviral particles expressed in the placenta.

                        Institute of Cancer Research, Chester Beatty Labs, Fulham Road, London.

 

1988 B.Sc.      Honours Degree in Bioanalytical Science (Class IIi).

                        Kingston Polytechnic, Surrey.

2004-2007       Senior Scientist, UCL (Biovex Ltd), The Windeyer Institute, London.

.

1999-2004       Scientist UCL (Biovex Ltd), The Windeyer Institute, London.

 

1995-1999              Research Associate, Prof Thomas F. Schulz, University of Liverpool.

•

1989-1995              Scientific Officer, Prof Robin Weiss, Institute of Cancer Research

Research Interests

Viral Vectors

Molecular Biology

Tumour Biology

Gene Therapy

Publications

Journal articles

  • Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS. (2012) 'Targeting the HOX/PBX dimer in breast cancer.'. Breast Cancer Res Treat, Netherlands: 136 (2), pp. 389-398.
    doi: 10.1007/s10549-012-2259-2
  • Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS. (2012) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. BRITISH JOURNAL OF CANCER, 106 (3), pp. 496-507.
    doi: 10.1038/bjc.2011.577
  • Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS. (2011) 'Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.'. BMC Cancer, England: 11
    doi: 10.1186/1471-2407-11-221
    Full text is available at: http://epubs.surrey.ac.uk/107390/

    Abstract

    Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly. Reoviruses have been shown to associate with microtubules and may require this association for efficient viral replication.

  • Wong J, Kelly K, Mittra A, Gonzalez SJ, Song KY, Simpson G, Coffin R, Fong Y. (2010) 'A Third-Generation Herpesvirus Is Effective Against Gastroesophageal Cancer'. ACADEMIC PRESS INC ELSEVIER SCIENCE JOURNAL OF SURGICAL RESEARCH, 163 (2), pp. 214-220.
    doi: 10.1016/j.jss.2010.03.021
  • Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS. (2010) 'The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 18 (12), pp. 2085-2093.
    doi: 10.1038/mt.2010.189
  • Anesti A-M, Simpson GR, Price T, Pandha HS, Coffin RS. (2010) 'Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 486
    doi: 10.1186/1471-2407-10-486
    Full text is available at: http://epubs.surrey.ac.uk/713427/
  • Price DL, Lin S-F, Wong J, Li S, Fong Y, Wong RJ, Lin S-F, Han Z, Simpson G, Coffin RS. (2010) 'Oncolysis using herpes simplex virus type 1 Engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma'. Archives of Otolaryngology - Head and Neck Surgery, 136 (2), pp. 151-158.
    doi: 10.1001/archoto.2009.214
  • Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R. (2009) 'Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 15 (19), pp. 6158-6166.
    doi: 10.1158/1078-0432.CCR-09-0796
    Full text is available at: http://epubs.surrey.ac.uk/227160/
  • Simpson GR, Coffin RS. (2009) 'Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control.'. Methods Mol Biol, United States: 542, pp. 551-564.
    doi: 10.1007/978-1-59745-561-9_29
  • Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS. (2007) 'Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.'. J Gene Med, England: 9 (2), pp. 99-106.
    doi: 10.1002/jgm.999
  • Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS. (2006) 'Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.'. Cancer Res, United States: 66 (9), pp. 4835-4842.
    doi: 10.1158/0008-5472.CAN-05-4352

Conference papers

  • Pandha S, Heinemann L, Simpson GR, Boxall A, Relph K, Morgan R. (2011) 'Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 47-48.
  • Pandha S, Simpson GR, Horvath A, Coffin RS, Pencavel T, Harrington K. (2011) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer (visualised by micro CT)'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 52-53.
  • Annels NE, Riley C, Bokaee S, Denyer M, Simpson GR, Pandha H. (2010) 'EN2: A Novel Immunotherapeutic Target for Melanoma'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 891-891.
    doi: 10.1097/CJI.0b013e3181f1e08d
  • Horvath A, Simpson GR, Coffin RS, Mostafid H, Pandha H. (2010) 'NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER USING A GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS'. ELSEVIER SCIENCE BV EUR UROL SUPPL, 9 (6), pp. 646-646.
    doi: 10.1016/S1569-9056(10)61634-X
  • Heinemann L, Simpson G, Harrington K, Melcher A, Coffey MC, Pandha HS. (2008) 'Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, Geneva, SWITZERLAND: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 6 (12), pp. 99-99.
    doi: 10.1016/S1359-6349(08)72242-0